FDA Calls For More Review Of Aortic Valve Reduced Leaflet Motion
This article was originally published in The Gray Sheet
The agency issued a notification that recent advanced imaging studies have shown reduced leaflet motion in bioprosthetic aortic valves. While FDA believes the devices are reasonably safe and effective, it is working with cardiology societies to design new clinical studies to explore the phenomenon.
You may also be interested in...
The worldwide voluntary removal comes in response to reports that the pin that connects the valve to the delivery system sometimes releases prematurely, most likely due to excess tension created during manufacturing.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add three new products, including Velsipity, Pfizer's treatment for moderately to severely active ulcerative colitis in patients 16 years of age and older.
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.